

NIH Innovation Account in 21st Century Cures

December 2016

The *21st Century Cures Act* (H.R. 34), which was approved, [392-26](#), by the House on Nov. 30, 2016, and by the Senate, [94-5](#), on Dec. 7, 2016, includes a number of provisions related to medical research. Division A, Sec. 1001, of the package establishes an Innovation Account with a total of \$4.796 billion through the NIH director for specific initiatives (“Innovation Projects”) at the National Institutes of Health (NIH) between fiscal years (FYs) 2017 and 2026:

- For the Precision Medicine Initiative (PMI), \$1.455 billion between FYs 2017 and 2026;
- For the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, \$1.511 billion between FYs 2017 and 2026;
- For cancer research, \$1.800 billion between FYs 2017 and 2023; and
- For clinical research to advance the field of regenerative medicine using adult stem cells, \$30 million between FYs 2017 and 2020, with a required match of \$1 non-Federal for every \$1 Federal.

For NIH to access the funding, which falls outside the discretionary budget caps, appropriators will need to release funding from the account each fiscal year, with specific limitations on funding available for each initiative. The funding levels available to appropriators for each initiative are outlined below by fiscal year. In addition to the Account, the annual spending bills will continue to include a base NIH appropriation that will support research across the agency.

The law also calls on NIH, after consulting with the Advisory Committee to the Director of NIH, to submit to the House and Senate Appropriations Committees, the House Energy and Commerce Committee, and the Senate Health, Education, Labor, and Pensions (HELP) Committee a work plan within 180 days of enactment with proposed allocations for the ten year period of the Account and how each supported project aligns with the NIH’s Strategic Plan, as well as an annual report. The measure also prohibits funds in the Account, which is scheduled to expire on Sept. 30, 2026, to be used for any purpose other than an NIH Innovation Project.

NIH Innovation Account Funding Levels (\$ in millions)

	PMI	BRAIN	Cancer	Regenerative Medicine ¹	Total
FY 2017 ²	40	10	300	2	352
FY 2018	100	86	300	10	496
FY 2019	186	115	400	10	711
FY 2020	149	140	195	8	492
FY 2021	109	100	195	0	404
FY 2022	150	152	194	0	496
FY 2023	419	450	216	0	1,085
FY 2024	235	172	--	0	407
FY 2025	36	91	--	0	127
FY 2026	31	195	--	0	226
Total	1,455	1,511	1,800	30	4,796

¹ Funding for clinical research to further the field of regenerative medicine using adult stem cells requires a non-Federal match of \$1 for every Federal \$1.

² The *Further Continuing and Security Assistance Appropriations Act, 2017*, provides the full \$352 million available to NIH in FY 2017.

Contact: Tannaz Rasouli, Executive Director, Ad Hoc Group for Medical Research
trasouli@aamc.org